Oculis (NASDAQ:OCS) Price Target Cut to $40.00 by Analysts at Stifel Nicolaus

Oculis (NASDAQ:OCS) had its target price cut by analysts at Stifel Nicolaus from $50.00 to $40.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ target price points to a potential upside of 173.19% from the company’s previous close.

Several other equities research analysts have also commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Oculis in a research report on Tuesday, April 21st. Needham & Company LLC decreased their target price on Oculis from $46.00 to $38.00 and set a “buy” rating on the stock in a research report on Monday. Guggenheim decreased their target price on Oculis from $75.00 to $45.00 and set a “buy” rating on the stock in a research report on Monday. Wall Street Zen lowered Oculis from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Finally, HC Wainwright decreased their price objective on shares of Oculis from $47.00 to $26.00 and set a “buy” rating on the stock in a report on Monday. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Oculis presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.75.

Oculis Stock Down 35.5%

Shares of OCS stock traded down $8.06 on Monday, hitting $14.64. The stock had a trading volume of 4,054,351 shares, compared to its average volume of 415,235. The company has a market cap of $848.94 million, a PE ratio of -6.87 and a beta of 0.23. The company has a quick ratio of 5.18, a current ratio of 5.18 and a debt-to-equity ratio of 0.01. The business has a 50 day moving average price of $27.68 and a 200 day moving average price of $25.21. Oculis has a one year low of $14.16 and a one year high of $34.47.

Oculis (NASDAQ:OCS) last announced its earnings results on Friday, May 8th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.14). The firm had revenue of $0.26 million during the quarter, compared to the consensus estimate of $0.25 million. Oculis had a negative return on equity of 56.78% and a negative net margin of 8,460.67%. Research analysts anticipate that Oculis will post -2.21 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Oculis

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE grew its holdings in Oculis by 9.1% in the first quarter. Bank of America Corp DE now owns 69,764 shares of the company’s stock valued at $1,855,000 after purchasing an additional 5,813 shares during the last quarter. Himension Capital Singapore PTE. LTD. acquired a new stake in Oculis during the 1st quarter valued at approximately $503,000. Koshinski Asset Management Inc. acquired a new stake in Oculis during the 1st quarter valued at approximately $238,000. Y Intercept Hong Kong Ltd acquired a new stake in Oculis during the 1st quarter valued at approximately $776,000. Finally, Perceptive Advisors LLC acquired a new stake in Oculis during the 4th quarter valued at approximately $9,862,000. Hedge funds and other institutional investors own 22.30% of the company’s stock.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.